Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qifangfeixian Granules for CTD-ILD
NCT06674148Phase 3Recruiting
- Start
- Oct 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Qifangfeixian granules in connective tissue disease-associated interstitial lung disease (CTD-ILD). Started Oct 2024; status: recruiting.
02
Drugs
Qifangfeixian granules
03
Conditions
connective tissue disease-associated interstitial lung disease (CTD-ILD)
Beyond the preview
Go deeper on NCT06674148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06674148.